NuGenerex Immuno-Oncology Inc (fka NUGX)

[docj]

MEMORANDUM OF UNDERSTANDING STATUS UPDATE ON THE MEMORANDUM OF UNDERSTANDING BETWEEN BINTAI HEALTHCARE SDN BHD AND GENEREX BIOTECHNOLOGY CORPORATION AND NUGENEREX IMMUNO-ONCOLOGY INC. (COLLECTIVELY REFERRED TO AS GENEREX)
BINTAI KINDEN CORPORATION BERHAD

Type Announcement
Subject MEMORANDUM OF UNDERSTANDING
Description STATUS UPDATE ON THE MEMORANDUM OF UNDERSTANDING BETWEEN BINTAI HEALTHCARE SDN BHD AND GENEREX BIOTECHNOLOGY CORPORATION AND NUGENEREX IMMUNO-ONCOLOGY INC. (COLLECTIVELY REFERRED TO AS GENEREX)
We refer to our announcements dated 25 November 2020 and 6 July 2021 in regards to the Memorandum of Understanding (“MOU”) entered into between Bintai Healthcare Sdn Bhd [Registration No. 202001027986 (1384306-P) (“BHSB”), a 50.05% owned subsidiary of the Company, and Generex for the proposed sole distribution rights for BHSB to market and supply the synthetic peptide vaccine for SARS-CoV-2 Coronavirus Vaccine to the Australia and New Zealand markets.



The Board of Directors of BKCB wishes to announce that as of todate, the MOU on the above matter remain status quo and any further development thereon shall be announced in due course.



This announcement is dated 6 October 2021.